Benefits
IBS symptom improvement
Enteric-coated peppermint oil (which delivers menthol to the small intestine) is among the better studied botanical approaches to IBS, and pooled analyses of those trials report a number needed to treat of roughly 4 for global symptom relief — about 1 person in 4 doing better than on placebo. Two things temper that: the trials tested whole peppermint oil rather than isolated menthol, and the largest and most rigorous single trial, described further down this page (Weerts, 190 patients), missed its primary abdominal-pain endpoint. The honest summary is a real but moderate average effect, not a substantial one. Main side effect is heartburn from gastric absorption, which proper enteric coating largely prevents. No guideline is cited anywhere on this page. Gastroenterology guidelines do discuss peppermint oil among the options for IBS, generally as a conditional suggestion rather than a strong recommendation. IBS is a diagnosed medical condition, so what to try and in what order is a decision for a clinician, not a supplement label.
Antispasmodic effect on GI cramping
Menthol relaxes intestinal smooth muscle, reducing the painful spastic contractions that drive IBS symptoms and functional cramping. In laboratory and animal tissue work this relaxing effect resembles what prescription antispasmodics do, and menthol does not act on the acetylcholine system those drugs work through, so it would not be expected to cause their dry mouth, blurred vision, or urinary retention. No head-to-head trial against dicyclomine or hyoscyamine is cited here, so this is a mechanistic comparison rather than a demonstrated clinical equivalence. Most useful for patients with cramping or pain-predominant IBS where smooth muscle hyperactivity drives symptoms.
Topical analgesia for muscle and joint pain
This is a topical use — menthol applied to the skin, not swallowed. Nothing here suggests that taking menthol by mouth relieves muscle or joint pain. Applied to the skin at 1-16%, menthol produces a cooling sensation followed by an analgesic effect that is useful for acute muscle and joint discomfort. FDA-approved over-the-counter active ingredient for musculoskeletal pain in countless products (Bengay, Icy Hot, Biofreeze, Tiger Balm). Evidence is stronger for acute pain than chronic conditions. Commonly used on the skin for post-exercise soreness and minor strains, and sometimes for joint pain. Whether a rub is a sensible alternative to an oral pain medicine is a question for a clinician, and none of this applies to menthol taken by mouth.
Respiratory symptom relief — sensation, not actual decongestion
Inhaled menthol vapours (a non-oral route) produce the sensation of improved nasal airflow during colds and flu, which is why it's the active ingredient in Vicks VapoRub®, inhalers, and lozenges. Important caveat: actual airflow measurements show menthol does not genuinely decongest or bronchodilate — the relief is symptomatic perception only. In the oral trial cited here (Eccles 1990: 62 people with colds, an 11 mg menthol lozenge), objectively measured nasal airway resistance did not change while the sensation of clearer breathing did, and an earlier study of inhaled menthol found no consistent effect on nasal resistance at all, concluding menthol has no true nasal decongestant action. Useful for comfort during respiratory infections; not a substitute for actual decongestants when objective airflow improvement is needed.
Mechanism of action
TRPM8 (cold receptor) agonism — the signature cooling effect
Menthol is the prototype TRPM8 agonist, activating this transient receptor potential channel that normally responds to cool temperatures (8-26°C). TRPM8 activation produces the perceived 'cooling' sensation without actual temperature change. Underlies effects on pain modulation (skin), perceived nasal airflow, and possibly some GI effects via enteric TRPM8.
L-type calcium channel blockade (antispasmodic)
L-menthol blocks voltage-gated L-type calcium channels in GI smooth muscle, producing antispasmodic effect comparable to dicyclomine but without anticholinergic systemic effects. This has been shown in isolated tissue and animal preparations, including colonic smooth muscle of the overactive type seen in diarrhea-predominant IBS. It is the leading proposed explanation for the global symptom improvement seen in pooled analyses of peppermint oil trials, but nothing of the kind was measured in those patients, so the link between the mechanism and the clinical result remains inferred.
Anti-inflammatory and antimicrobial activities
In cell and animal studies, menthol lowers inflammatory signalling molecules such as TNF-α and IL-6 and shows mild antimicrobial activity against a range of gut bacteria. Whether any of this happens at the doses people actually take is untested: no study cited on this page measured inflammatory markers, gut bacteria, or small intestinal bacterial overgrowth (SIBO) in humans, and the idea that these activities add up alongside the antispasmodic effect is a hypothesis rather than a finding.
5-HT3 antagonism and visceral hypersensitivity reduction
Menthol shows weak activity at the 5-HT3 receptor in laboratory assays — the same receptor blocked by ondansetron-class antiemetics, though menthol is far weaker there than those drugs. This has been proposed as a way it might dampen visceral hypersensitivity, the pattern in IBS where ordinary gut stretching is felt as pain. It remains a proposed explanation; no trial cited here tested whether it accounts for any of the abdominal-pain reduction observed.
Clinical trials
Evidence review and pooled analysis (Alammar N, Wang L, Saberi B, Nanavati J, Holtmann G, Shinohara RT, Mullin GE 2019, BMC Complement Altern Med 19(1):21, doi:10.1186/s12906-018-2409-0).
12 clinical trials with 835 patients with IBS comparing peppermint oil vs placebo. PRISMA-compliant; PROSPERO registered.
Peppermint oil significantly improved global IBS symptoms: RR 2.39 (95% CI 1.93-2.97), I²=0% (no heterogeneity), z=7.93 (p<0.00001). Abdominal pain also significantly reduced. NNT approximately 4. Adverse events more common in PO group, mainly heartburn from premature gastric absorption — relevant only for non-enteric-coated formulations. A widely cited pooled analysis supporting peppermint oil for IBS. Two limits on how far it carries: it pools trials of whole peppermint oil rather than isolated menthol, and it predates the largest single trial in this field (Weerts, described below), which missed its primary endpoint — so later summaries read this pooled estimate with caveats.
4-week double-blind placebo-controlled clinical trial (Cash BD, Epstein MS, Shah SM 2016, Dig Dis Sci 61(2):560-571, doi:10.1007/s10620-015-3858-7).
72 patients with IBS-M or IBS-D meeting Rome III criteria. Novel formulation of peppermint oil designed for sustained release in small intestine (avoiding gastric absorption that causes heartburn). 3x/day dosing.
Significant improvements in Total IBS Symptom Score (TISS) at both 24 hours (early relief) and 4 weeks vs placebo. Abdominal pain, bloating, urgency, and straining all improved. Excellent tolerability with novel formulation reducing heartburn issue from earlier PO products. This was one 72-patient trial of a single commercial formulation, so it suggests rather than establishes that targeted small-intestinal delivery gives both rapid (24-hour) and sustained (4-week) relief. Independent replication is what would settle it.
Multicenter double-blind clinical trial (Weerts ZZRM, Masclee AAM, Witteman BJM, Clemens CHM, Winkens B, Brouwers JRBJ, Frijlink HW, Muris JWM, De Wit NJ, Essers BAB, Tack J, Snijkers JTW, Bours AMH, de Ruiter-van der Ploeg AS, Jonkers DMAE, Gastroenterology 158(1):123-136, doi:10.1053/j.gastro.2019.08.026).
190 IBS patients (Rome IV) at 4 Netherlands hospitals. Randomized to small-intestinal-release PO 182 mg, ileocolonic-release PO 182 mg, or placebo for 8 weeks.
Primary endpoint (≥30% abdominal pain response per FDA criteria) not MET for either formulation — challenging earlier optimism. However, secondary outcomes of abdominal pain (P=0.016), discomfort (P=0.020), and IBS severity (P=0.020) were improved by small-intestinal PO. Mixed results: large rigorous trial showing more modest effect size than pooled analyses suggested. This trial is the main reason the earlier pooled estimates are now read with caveats. The current view is a moderate but real benefit, less dramatic than the pooled analyses alone suggested.